- According to estimates from 28 analysts, Neurocrine Biosciences, Inc. stock's average price target has risen from $201.2 to $209.34, with forecasts ranging from $175 to $249 per share
- Based on the Jul. 30 closing price, the updated target implies approximately 13% potential upside
- Consensus rating remains at “Buy” across 31 covering analysts, with 27 Buys, 4 Holds and 0 Sells
Explore more price target data and ratings for Neurocrine Biosciences, Inc. on the , and track all previous and future analyst recommendations for Neurocrine Biosciences, Inc. in the dedicated .
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.